从遗传角度鉴定子宫内膜异位症的潜在诊断生物标志物和药物标:孟德尔的随机化研究
Yingjia Zhu1, Feng Cheng2, Linling Zhu1
1Department of Gynecology, Hangzhou Women's Hospital, Hangzhou, China.
Gynecologic and obstetric investigation
|February 20, 2025
概括
这项研究确定了7个基因作为子宫内膜异位症 (EM) 的潜在诊断标志物,4个基因作为药物标,为精准医学提供了新的途径. 需要进一步的研究来验证这些遗传发现,以改善EM诊断和治疗.
科学领域:
- 遗传学和生殖健康 遗传学和生殖健康
- 生物标志物发现发现
- 药物基因组学 药物基因组学
背景情况:
- 子宫内膜异位症 (EM) 是一种具有不明原因的慢性生殖系统疾病.
- 了解EM病原体对于改善患者的生活质量至关重要.
- 遗传因素在EM发育和进展中起着重要作用.
研究的目的:
- 确定用于EM诊断的新型遗传生物标志物.
- 为了发现EM治疗的潜在药物点.
- 探索基于遗传见解的EM个性化治疗策略.
主要方法:
- 基于总结数据的门德尔随机化 (SMR) 分析,使用cis-eQTL和FinnGen数据库数据.
- 生物信息学分析,临床样本的RT-qPCR验证.
- 局部化和分子对接用于药物标查.
主要成果:
- 七个基因 (EEFSEC,INO80E,RAP1GAP,LDAH,RSPRY1,HCG22,ADK) 被确定为潜在的EM诊断标记物.
- 四个基因 (EEFSEC,HCG22,INO80E,RSPRY1) 被确定为潜在的药物标.
- 基因分析为EM病因学和病变发生提供了新的见解.
结论:
- 该研究成功地确定了EM的潜在遗传诊断标记物和药物标.
- 这些发现为EM药物开发和精密医学提供了新的方向.
- 局限性包括SMR偏差,类型和验证范围.
相关概念视频
Genetic Screens
Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...


